

Title	New generation trimethylangelicin (TMA) analogues for selective modulation of defective CFTR or inflammation
PI	CHILIN Adriana
Research Group	Medicinal Chemistry – DSF
Curriculum	Scienze Farmaceutiche
Contact	web: http://www.dsfarm.unipd.it/drug-design-and-synthesis
	email: adriana.chilin@unipd.it

Project description:

TMA was recently identified as a promising anti-inflammatory molecule for CF lung disease, with additional properties as potentiator and corrector of mutated F508del CFTR protein.

The major objective is to synthesize TMA analogs with the aim to find new anti-inflammatory agents (with NF- κ B inhibitory activity) and/or CFTR function modulators, useful for CF lung disease, with equal or higher activity in the respect to the parent TMA, but with low or absent DNA photo-binding properties. Hence, the goals of the project can be outlined in: 1) design and synthesis of a library of TMA analogs to identify a lead compound with optimized properties, 2) test of photo-reactivity, 3) test of the anti-inflammatory activity and of the effects as CFTR function modulators, 4) derivation of structure-activity relationships to rationalize the structural determinants required to obtain selective anti-inflammatory properties, selective CFTR modulatory properties and dual anti-inflammatory/CFTR modulatory activity.

Expected results. Identification of novel candidates with improved anti-inflammatory and/or CFTR function modulating properties with reduced photoreactivity for the treatment of the chronic lung pathology of patients affected by CF.

Recent Publications in the specific field:

M Borgatti, A Chilin, et al. *Eur.J.Med.Chem.*, **46**, 4870-7 (2011) DOI:10.1016/j.ejmech.2011.07.032

G Marzaro, ... A Chilin, *J. Med. Chem.* **67**, 373-83 (2013) DOI: 10.1021/jm3009647

G Marzaro, ... A Chilin, *Molecular Diversity* **19**, 551-61 (2015) DOI: 10.1007/s11030-015-9586-2

I. Lampronti, A Chilin, *Mediators of inflammation*, 2017, article ID 2389487
DOI:10.1155/2017/238948.

G. Marzaro, ... A Chilin, *Eur.J.Med.Chem.*, **151**, 285-293 (2018), DOI: 10.1016/j.ejmech.2018.03.080

O. Laselva, ... A. Chilin, *Frontiers in Pharmacology*, **9**, 719 (2018) DOI:10.3389/fphar.2018.00719

Collaborations/Network:

Dr. Cabrini/Dr. Dehecchi - Laboratory of Molecular Pathology - University Hospital of Verona.

Prof. Gambari - Department of Life Sciences and Biotechnology, University of Ferrara.

Prof. Lukacs - Department of Physiology, McGill University, Montréal, Québec

Research funding:

FFC projects (Fondazione Ricerca Fibrosi Cistica), PRID UNIPD